Logo do repositório
 
Publicação

Rituximab in connective tissue disease–associated interstitial lung disease

2019Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorDuarte, Ana Catarina
dc.contributor.authorCordeiro, Ana
dc.contributor.authorFernandes, Bruno Miguel
dc.contributor.authorBernardes, Miguel
dc.contributor.authorMartins, Patrícia
dc.contributor.authorCordeiro, Inês
dc.contributor.authorSantiago, Tânia
dc.contributor.authorSeixas, Maria Inês
dc.contributor.authorRibeiro, Ana Roxo
dc.contributor.authorSantos, Maria
dc.date.accessioned2022-05-12T15:51:38Z
dc.date.available2022-05-12T15:51:38Z
dc.date.issued2019
dc.description© International League of Associations for Rheumatology (ILAR) 2019pt_PT
dc.description.abstractIntroduction/objectives: To evaluate rituximab (RTX) effectiveness and safety in patients with interstitial lung disease (ILD) related to connective tissue diseases (CTD). Methods: Retrospective multicenter cohort study, including patients with CTD-ILD, followed in six Portuguese rheumatology departments until November 2018. ILD diagnosis was based on high-resolution CT (HRCT) and/or lung biopsy. Results of HRCT, pulmonary function tests, and 6-min walking test before and after RTX were compared using the Wilcoxon matched pair test. Safety, including adverse events during treatment and reasons for RTX discontinuation, was also analyzed. Results: A total of 49 patients were included, with rheumatoid arthritis being the commonest CTD (61.2%). The median interval between CTD onset and ILD diagnosis was 4 years (IQR 1-9.5) and median ILD duration at first RTX administration was 1 year (IQR 0-4). The median RTX treatment duration until the last follow-up was 3 years (IQR 1-6). Usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) were the commonest patterns, occurring in 20 and 18 patients, respectively. One year after RTX first administration, there was a stabilization in carbon monoxide diffusing capacity (DLCO; mean + 5.4%, p = 0.12) and improvement in forced vital capacity (FVC; mean + 4.3%, p = 0.03), particularly in patients with NSIP. Patients with UIP had less promising results, but at 1 year, pulmonary function tests remained stable (DLCO + 2.5%, p = 0.77; FVC + 4.2%, p = 0.16). Infection was the main reason for RTX discontinuation and led to two deaths. Conclusions: RTX seems to be a promising treatment for CTD-ILD patients, particularly when NSIP pattern is present. Key points • The use of rituximab in patients with interstitial lung disease related to connective tissue disease is associated with long-standing disease stability in a wide range of systemic rheumatic diseases. • Efficacy results were particularly impressive in patients with non-specific interstitial pneumonia pattern, although in a subgroup of patients with usual interstitial pneumonia pattern, disease progression was also hold with this treatment. • In a large number of patients, rituximab was used in monotherapy and as first-line treatment.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationClin Rheumatol 38, 2001–2009 (2019)pt_PT
dc.identifier.doi10.1007/s10067-019-04557-7pt_PT
dc.identifier.eissn1434-9949
dc.identifier.issn0770-3198
dc.identifier.urihttp://hdl.handle.net/10451/52957
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.relation.publisherversionhttps://www.springer.com/journal/10067pt_PT
dc.subjectConnective tissue diseasept_PT
dc.subjectInterstitial lung diseasept_PT
dc.subjectNon-specific interstitial pneumoniapt_PT
dc.subjectRituximabpt_PT
dc.subjectUsual interstitial pneumoniapt_PT
dc.titleRituximab in connective tissue disease–associated interstitial lung diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2009pt_PT
oaire.citation.issue7pt_PT
oaire.citation.startPage2001pt_PT
oaire.citation.titleClinical Rheumatologypt_PT
oaire.citation.volume38pt_PT
person.familyNameMartins
person.familyNameCordeiro
person.familyNameSantos
person.givenNamePatrícia
person.givenNameInês
person.givenNameMaria Jose
person.identifier.ciencia-id441A-CD98-8FD6
person.identifier.orcid0000-0003-3578-7213
person.identifier.orcid0000-0001-9308-6728
person.identifier.orcid0000-0002-7946-1365
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication28ce5691-575c-4bf4-9428-58ce9acefef7
relation.isAuthorOfPublicatione9947f3d-8ed6-4b80-b4b9-96baa387baf7
relation.isAuthorOfPublication288e25e9-3f56-4cab-afff-0cda5478f1ba
relation.isAuthorOfPublication.latestForDiscoverye9947f3d-8ed6-4b80-b4b9-96baa387baf7

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Rituximab_connective.pdf
Tamanho:
446.53 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM-CUR-Artigos em Revistas Internacionais